



US008337888B2

(12) **United States Patent**
Wright et al.

(10) **Patent No.:** **US 8,337,888 B2**
(45) **Date of Patent:** ***Dec. 25, 2012**

- (54) **PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT**
- (75) Inventors: **Curtis Wright**, Norwalk, CT (US); **Benjamin Oshlack**, New York, NY (US); **Christopher Breder**, Greenwich, CT (US)
- (73) Assignee: **Purdue Pharma L.P.**, Stamford, CT (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.
- (21) Appl. No.: **13/349,449**
- (22) Filed: **Jan. 12, 2012**
- (65) **Prior Publication Data**
US 2012/0108622 A1 May 3, 2012

Related U.S. Application Data

- (63) Continuation of application No. 12/653,115, filed on Dec. 8, 2009, now abandoned, which is a continuation of application No. 10/214,412, filed on Aug. 6, 2002, now abandoned.
- (60) Provisional application No. 60/310,534, filed on Aug. 6, 2001.
- (51) **Int. Cl.**
A61K 9/20 (2006.01)
- (52) **U.S. Cl.** **424/464; 424/465**
- (58) **Field of Classification Search** None
See application file for complete search history.

References Cited

U.S. PATENT DOCUMENTS

3,065,143 A	11/1962	Christenson et al.
3,133,132 A	5/1964	Loeb et al.
3,173,876 A	3/1965	Zobrist et al.
3,260,646 A	7/1966	Paulsen et al.
3,276,586 A	10/1966	Rosaen
3,541,005 A	11/1970	Strathmann et al.
3,541,006 A	11/1970	Bixler et al.
3,546,876 A	12/1970	Fokker et al.
3,845,770 A	11/1974	Theeuwes et al.
3,916,889 A	11/1975	Russell
3,980,766 A	9/1976	Shaw et al.
4,063,064 A	12/1977	Saunders et al.
4,070,494 A	1/1978	Hoffmeister et al.
4,088,864 A	5/1978	Theeuwes et al.
4,160,020 A	7/1979	Ayer et al.
4,175,119 A	11/1979	Porter
4,200,098 A	4/1980	Ayer et al.
4,285,987 A	8/1981	Ayer et al.
4,293,539 A	10/1981	Ludwig et al.
4,385,057 A	5/1983	Bjork et al.
4,389,393 A	6/1983	Schor et al.
4,424,205 A	1/1984	LaHann et al.
4,457,933 A	7/1984	Gordon et al.
4,459,278 A	7/1984	Porter
4,588,580 A	5/1986	Gale et al.

4,599,342 A	7/1986	LaHann
4,610,870 A	9/1986	Jain et al.
4,666,705 A	5/1987	DeCrosta et al.
4,769,372 A	9/1988	Kreek
4,785,000 A	11/1988	Kreek et al.
4,806,341 A	2/1989	Chien et al.
4,812,446 A	3/1989	Brand
4,861,598 A	8/1989	Oshlack
4,957,681 A	9/1990	Klimesch et al.
4,990,341 A	2/1991	Goldie et al.
5,026,556 A	6/1991	Drust et al.
5,059,600 A	10/1991	Gawin et al.
5,069,909 A	12/1991	Sharma et al.
5,111,942 A	5/1992	Bernardin
5,114,942 A	5/1992	Gawin et al.
5,130,311 A	7/1992	Guillaumet et al.
5,149,538 A	9/1992	Granger et al.
5,215,758 A	6/1993	Krishnamurthy
5,225,199 A	7/1993	Hidaka et al.
5,240,711 A	8/1993	Hille et al.
5,266,331 A	11/1993	Oshlack et al.
5,273,758 A	12/1993	Royce
5,273,760 A	12/1993	Oshlack et al.
5,286,493 A	2/1994	Oshlack et al.
5,290,816 A	3/1994	Blumberg
5,321,012 A	6/1994	Mayer et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0661045 7/1995

(Continued)

OTHER PUBLICATIONS

Remington's Pharmaceutical Sciences (Arthur Osol, ed.) pp. 1553-1593 (1980). Ton et al., British Journal of Pharmacology, vol. 10, pp. 175-182 (1955).
 U.S. Appl. No. 10/214,412: Final Office Action dated Jun. 8, 2009 (23 pages).
 U.S. Appl. No. 10/214,412: Final Office Action dated Mar. 29, 2006 (19 pages).
 U.S. Appl. No. 10/214,412: Final Office Action dated Oct. 9, 2007 (18 pages).
 U.S. Appl. No. 10/214,412: Non-Final Office Action dated Feb. 22, 2008 (15 pages).
 U.S. Appl. No. 10/214,412: Non-Final Office Action dated Jul. 18, 2005 (13 pages).
 U.S. Appl. No. 10/214,412: Non-Final Office Action dated Jan. 5, 2007 (19 pages).

(Continued)

Primary Examiner — Robert A Wax
Assistant Examiner — Olga V Tcherkasskaya
(74) *Attorney, Agent, or Firm* — Lowenstein Sandler PC

(57) **ABSTRACT**

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

24 Claims, No Drawings

U.S. PATENT DOCUMENTS

5,324,351	A	6/1994	Oshlack et al.	
5,330,766	A	7/1994	Morella et al.	
5,356,467	A	10/1994	Oshlack et al.	
5,376,705	A	12/1994	Leys et al.	
5,403,868	A	4/1995	Reid et al.	
5,409,944	A	4/1995	Black et al.	
5,436,265	A	7/1995	Black et al.	
5,472,712	A	12/1995	Oshlack et al.	
5,472,943	A	12/1995	Crain et al.	
5,474,995	A	12/1995	Ducharme et al.	
5,500,227	A	3/1996	Oshlack et al.	
5,502,058	A	3/1996	Mayer et al.	
5,508,042	A	4/1996	Oshlack et al.	
5,510,368	A	4/1996	Lau et al.	
5,514,680	A	5/1996	Weber et al.	
5,521,213	A	5/1996	Prasit et al.	
5,536,752	A	7/1996	Ducharme et al.	
5,549,912	A	8/1996	Oshlack et al.	
5,550,142	A	8/1996	Ducharme et al.	
5,552,422	A	9/1996	Gauthier et al.	
5,556,838	A	9/1996	Mayer et al.	
5,580,578	A	12/1996	Oshlack et al.	
5,593,994	A	1/1997	Batt et al.	
5,604,253	A	2/1997	Lau et al.	
5,604,260	A	2/1997	Guay et al.	
5,616,601	A	4/1997	Khanna et al.	
5,639,476	A	6/1997	Oshlack et al.	
5,639,780	A	6/1997	Lau et al.	
5,656,295	A	8/1997	Oshlack et al.	
5,672,360	A	9/1997	Sackler et al.	
5,679,650	A	10/1997	Fukunaga et al.	
5,681,585	A	10/1997	Oshlack et al.	
5,695,781	A	12/1997	Zhang et al.	
5,741,524	A	4/1998	Staniforth et al.	
5,762,963	A	6/1998	Byas-Smith	
5,849,240	A *	12/1998	Miller et al.	264/460
5,891,471	A *	4/1999	Miller et al.	424/468
5,891,919	A	4/1999	Blum et al.	
5,965,163	A *	10/1999	Miller et al.	424/468
5,968,551	A	10/1999	Oshlack et al.	
6,024,982	A	2/2000	Oshlack et al.	
6,143,322	A	11/2000	Sackler et al.	
6,153,621	A	11/2000	Hamann	
6,162,467	A *	12/2000	Miller et al.	424/468
6,228,863	B1	5/2001	Palermo et al.	
6,277,398	B1	8/2001	Caruso	
6,309,668	B1	10/2001	Bastin et al.	
6,352,721	B1	3/2002	Faour	
6,375,957	B1 *	4/2002	Kaiko et al.	424/400
6,419,954	B1	7/2002	Chu	
6,440,464	B1	8/2002	Hsia et al.	
6,488,963	B1	12/2002	McGinity	
6,491,949	B2	12/2002	Faour et al.	
6,559,159	B2	5/2003	Carroll et al.	
6,572,885	B2	6/2003	Oshlack et al.	
6,593,367	B1	7/2003	Dewey et al.	
6,627,635	B2	9/2003	Palermo et al.	
6,696,088	B2	2/2004	Oshlack et al.	
7,201,920	B2	4/2007	Kumar et al.	
7,776,314	B2	8/2010	Bartholomaeus	
7,842,307	B2 *	11/2010	Oshlack et al.	424/450
8,075,872	B2	12/2011	Arkenau-Maric	
8,114,383	B2	2/2012	Bartholomaeus	
8,114,384	B2	2/2012	Arkenau	
8,192,722	B2	6/2012	Arkenau-Maric	
2003/0004177	A1 *	1/2003	Kao et al.	514/282
2003/0026838	A1	2/2003	Farrell	
2003/0059471	A1	3/2003	Compton et al.	
2003/0064099	A1	4/2003	Oshlack et al.	
2003/0064122	A1	4/2003	Goldberg et al.	
2003/0068276	A1	4/2003	Hughes et al.	
2003/0068370	A1	4/2003	Sackler	
2003/0068375	A1 *	4/2003	Wright et al.	424/468
2003/0068392	A1	4/2003	Sackler	
2003/0124061	A1	7/2003	Roberts	
2003/0124185	A1	7/2003	Oshlack et al.	
2003/0125347	A1	7/2003	Anderson et al.	
2003/0126428	A1	7/2003	Liu et al.	

2003/0170181	A1	9/2003	Midha	
2003/0232081	A1	12/2003	Doshi et al.	
2004/0126428	A1	7/2004	Hughes et al.	
2004/0131552	A1	7/2004	oehm	
2004/0151791	A1	8/2004	Mayo-Alvarez et al.	
2004/0228802	A1	11/2004	Chang et al.	
2004/0253310	A1 *	12/2004	Fischer et al.	424/472
2005/0020613	A1	1/2005	Boehm et al.	
2005/0063909	A1	3/2005	Wright et al.	
2005/0106249	A1	5/2005	Hwang et al.	
2005/0112067	A1	5/2005	Kumar et al.	
2005/0163717	A1	7/2005	Anderson et al.	
2005/0186139	A1	8/2005	Bartholomaeus	
2005/0214223	A1	9/2005	Bartholomaeus et al.	
2005/0236741	A1	10/2005	Arkenau	
2006/0002860	A1	1/2006	Bartholomaeus	
2006/0018837	A1	1/2006	Preston et al.	
2006/0039864	A1	2/2006	Bartholomaeus	
2006/0165790	A1 *	7/2006	Walden et al.	424/468
2006/0188447	A1	8/2006	Arkenau-Maric	
2006/0193782	A1	8/2006	Bartholomaeus	
2007/0003616	A1	1/2007	Arkenau-Maric	
2007/0003617	A1 *	1/2007	Fischer et al.	424/468
2007/0166234	A1	7/2007	Kumar et al.	
2007/0264327	A1	11/2007	Kumar et al.	
2008/0063725	A1 *	3/2008	Guimberteau et al.	424/492
2008/0254123	A1 *	10/2008	Fischer et al.	424/486
2008/0260815	A1 *	10/2008	Hayes et al.	424/455

FOREIGN PATENT DOCUMENTS

EP	1293195	A1	3/2003
JP	01236298	A	9/1989
WO	WO-95/20947	A1	8/1995
WO	WO-99/32119	A1	7/1999
WO	WO-01/58447	A1	8/2001
WO	WO-02/094254	A2	11/2002
WO	WO-03/015531	A2	2/2003
WO	WO-03/026743	A2	4/2003
WO	WO-03/092676	A1	11/2003
WO	WO-2004/026256	A2	1/2004
WO	WO-2004/026283	A1	4/2004
WO	WO-2004/037259	A1	5/2004
WO	WO-2005/053587	A1	6/2005

OTHER PUBLICATIONS

U.S. Appl. No. 10/214,412: Non-Final Office Action dated Nov. 1, 2004 (17 pages).

U.S. Appl. No. 12/262,015: Final Office Action dated Mar. 31, 2010 (32 pages).

U.S. Appl. No. 12/262,015: Non-Final Office Action dated Apr. 28, 2009 (20 pages).

Office Action mailed Sep. 11, 2007 in U.S. Appl. No. 11/136,636 of Emigh et al.

Office Action mailed Jun. 14, 2007 in U.S. Appl. No. 11/136,636 of Emigh et al.

Office Action mailed Jan. 23, 2007 in U.S. Appl. No. 11/136,636 of Emigh et al.

Office Action mailed Oct. 30, 2006 in U.S. Appl. No. 11/136,636 of Emigh et al.

Wells, Mickey L, and Eugene L. Parrott. 1992. Effect of Anionic Surfactants on the Release of Chlorpheniramine Maleate from an Inert, Heterogeneous Matrix. *Drug Development and Industrial Pharmacy* 18(2):175-186.

Rao, B. Sreenivasa and K.V. Ramana Murthy. 2000. Effect of Sodium Lauryl Sulfate on the Release of Rifampicin from Guar Gum Matrix. *Indian Journal of Pharmaceutical Science*:404-406.

Matschiner et al. 1995. Characterization of Ion Pair Formation Between Erythromycin and Lipophilic Counter Ions. *Pharmazie* 50:462-464.

Paragraph IV Patent Certification Notice for ANDA 202434 (2011).

Paragraph IV Patent Certification Notice for ANDA 203235 (2011).

Paragraph IV Patent Certification Notice for ANDA 202372 (2011).

Paragraph IV Patent Certification Notice for ANDA 202483 (2011).

Paragraph IV Patent Certification Notice for ANDA 202762 (2011).

Paragraph IV Patent Certification Notice for Amendment to ANDA 202762 (2011).

Paragraph IV Patent Certification Notice for ANDA 202455 (2011).

Paragraph IV Patent Certification Notice for ANDA 202352 (2011).

Woodburn, K.R., et al., "Vascular Complications of Injecting Drug Misuse", *British Journal of Surgery*, 1996, vol. 83, p. 1329-1334.

Kim, C., "Drug Release from Compressed Hydrophilic POLYOX-WSR Tablets", *Journal of Pharmaceutical Sciences*, vol. 84, No. 3, Mar. 1995, p. 303-306.

Apicella, A., "Poly(ethylene oxide) (PEO) and Different Molecular Weight PEO Blends Monolithic Devices for Drug Release", *Biomaterials*, vol. 14, No. 2, 1993, p. 83-90.

Deighan, C.J., et al., "Rhabdomyolysis and Acute Renal Failure Resulting From Alcohol and Drug Abuse", *QJ Med*, vol. 93, 2000, p. 29-33.

Kalant, H., et al., "Death in Amphetamine Users: Causes and Rates", *CMA Journal*, vol. 112, Feb. 8, 1975, p. 299-304.

U.S. Pharmacopeia, p. 2206, 1995.

U.S. Appl. No. 12/262,015—Non-Final Rejection dated Feb. 29, 2012.

U.S. Appl. No. 12/262,015—Response/Amendment dated Aug. 29, 2012.

* cited by examiner

1

**PHARMACEUTICAL FORMULATION
CONTAINING GELLING AGENT**

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/653,115, filed Dec. 8, 2009, which is a continuation of U.S. patent application Ser. No. 10/214,412, filed Aug. 6, 2002, which claims the benefit of U.S. Provisional Application No. 60/310,534, filed Aug. 6, 2001. The contents of these applications are hereby incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

Opioid analgesics are sometimes the subject of abuse. Typically, a particular dose of an opioid analgesic is more potent when administered parenterally as compared to the same dose administered orally. Therefore, one popular mode of abuse of oral opioid formulations involves the extraction of the opioid from the dosage form, and the subsequent injection of the opioid (using any "suitable" vehicle for injection) in order to achieve a "high." Also, some formulations can be tampered with in order to provide the opioid agonist contained therein better available for illicit use. For example, a controlled release opioid agonist formulation can be crushed in order to provide the opioid contained therein available for immediate release upon oral or nasal administration. An opioid formulation can also be abusable by administration of more than the prescribed dose of the drug.

Opioid antagonists have been combined with certain opioid agonists in order to deter the parenteral abuse of opioid agonists. In the prior art, the combination of immediate release pentazocine and naloxone has been utilized in tablets available in the United States, commercially available as Talwin®Nx from Sanofi-Winthrop. Talwin®Nx contains immediate release pentazocine hydrochloride equivalent to 50 mg base and naloxone hydrochloride equivalent to 0.5 mg base. A fixed combination therapy comprising tilidine (50 mg) and naloxone (4 mg) has been available in Germany for the management of pain since 1978 (Valoron®N, Goedecke). A fixed combination of buprenorphine and naloxone was introduced in 1991 in New Zealand (Temgesic®Nx, Reckitt & Colman) for the treatment of pain.

Purdue Pharma EP currently markets sustained-release oxycodone in dosage forms containing 10, 20, 40, and 80 mg oxycodone hydrochloride under the tradename OxyContin.

U.S. Pat. Nos. 5,266,331; 5,508,042; 5,549,912 and 5,656,295 disclose sustained release oxycodone formulations.

U.S. Pat. Nos. 4,769,372 and 4,785,000 to Kreek describe methods of treating patients suffering from chronic pain or chronic cough without provoking intestinal dysmotility by administering 1 to 2 dosage units comprising from about 1.5 to about 100 mg of opioid analgesic or antitussive and from about 1 to about 18 mg of an opioid antagonist having little to no systemic antagonist activity when administered orally, from 1 to 5 times daily.

U.S. Pat. No. 6,228,863 to Palermo et al. describes compositions and methods of preventing abuse of opioid dosage forms.

WO 99/32119 to Kaiko et al. describes compositions and methods of preventing abuse of opioid dosage forms.

U.S. Pat. No. 5,472,943 to Crain et al. describes methods of enhancing the analgesic potency of bimodally acting opioid agonists by administering the agonist with an opioid antagonist.

2

U.S. Pat. No. 3,980,766 to Shaw et al., is related to drugs which are suitable for therapy in the treatment of narcotic drug addiction by oral use, e.g., methadone, formulated to prevent injection abuse through concentration of the active component in aqueous solution by incorporating in a solid dosage or tablet form of such drug an ingestible solid having thickening properties which cause rapid increase in viscosity upon concentration of an aqueous solution thereof.

However, there still exists a need for a safe and effective treatment of pain with opioid analgesic dosage forms which are less subject to abuse than current therapies.

All documents cited herein, including the foregoing, art incorporated by reference in their entirety for all purposes.

OBJECTS AND SUMMARY OF THE
INVENTION

It is an object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less parenteral abuse than other dosage forms.

It is an object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less intranasal abuse than other dosage forms.

It is an object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less oral abuse than other dosage forms.

It is a further object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less diversion than other dosage forms.

It is a further object of certain embodiments of the invention to provide a method of treating pain in human patients with an oral dosage form of an opioid analgesic while reducing the abuse potential of the dosage form.

It is a further object of certain embodiments of the invention to provide a method of manufacturing an oral dosage form of an opioid analgesic such that it has less abuse potential.

These objects and others are achieved by the present invention, which is directed in part to an oral dosage form comprising an opioid analgesic; and at least one aversive agent for reducing the abuse of the opioid analgesic.

In certain embodiments of the present invention, the oral dosage forms of the present invention comprising an opioid analgesic; and an aversive agent or agents as a component(s) of the dosage form helps to prevent injection, inhalation, and/or oral abuse by decreasing the "attractiveness" of the dosage form to a potential abuser.

In certain embodiments of the present invention, the dosage form comprises an aversive agent such as a bittering agent to discourage an abuser from tampering with the dosage form and thereafter inhaling or swallowing the tampered dosage form. Preferably, the bittering agent is released when the dosage form is tampered with and provides an unpleasant taste to the abuser upon inhalation and/or swallowing of the tampered dosage form.

In certain embodiments of the present invention, the dosage form comprises an aversive agent such as an irritant to discourage an abuser from tampering with the dosage form and thereafter inhaling, injecting, or swallowing the tampered dosage form. Preferably, the irritant is released when the dosage form is tampered with and provides a burning or irritating effect to the abuser upon inhalation, injection, and/or swallowing of the tampered dosage form.

In certain embodiments of the present invention, the dosage form comprises an aversive agent such as a gelling agent to discourage an abuser from tampering with the dosage form and thereafter inhaling, injecting, and/or swallowing the tam-

3

pered dosage form. Preferably, the gelling agent is released when the dosage form is tampered with and provides a gel-like quality to the tampered dosage form which slows the absorption of the opioid analgesic such that an abuser is less likely to obtain a rapid "high". In certain preferred embodiments, when the dosage form is tampered with and exposed to a small amount (e.g., less than about 10 ml) of an aqueous liquid (e.g., water), the dosage form will be unsuitable for injection and/or inhalation. Upon the addition of the aqueous liquid, the tampered dosage form preferably becomes thick and viscous, rendering it unsuitable for injection. The term "unsuitable for injection" is defined for purposes of the present invention to mean that one would have substantial difficulty injecting the dosage form (e.g., due to pain upon administration or difficulty pushing the dosage form through a syringe) due to the viscosity imparted on the dosage form, thereby reducing the potential for abuse of the opioid analgesic in the dosage form. In certain embodiments, the gelling agent is present in such an amount in the dosage form that attempts at evaporation (by the application of heat) to an aqueous mixture of the dosage form in an effort to produce a higher concentration of the therapeutic agent, produces a highly viscous substance unsuitable for injection.

When nasally inhaling the tampered dosage form, the gelling agent can become gel like upon administration to the nasal passages due to the moisture of the mucous membranes. This also makes such formulations aversive to nasal administration, as the gel will stick to the nasal passage and minimize absorption of the abusable substance. In certain embodiments of the present invention, the dosage form comprises a combination of any or all of the aforementioned aversive agents (e.g., a bittering agent, an irritant, and/or a gelling agent) to discourage an abuser from tampering with the dosage form and thereafter inhaling, injecting, and/or swallowing the tampered dosage form.

Embodiments specifically contemplated include bittering agent; gelling agent; irritant; bittering agent and gelling agent; bittering agent and irritant; gelling agent and irritant; and bittering agent and gelling agent and irritant.

In certain preferred embodiments, the dosage forms are controlled release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic with one or more of the aversive agents described above such that the dosage form provides effective pain relief for at least about 12 hours, or at least about 24 hours when orally administered to a human patient.

In certain embodiments of the present invention the aversive agent present in the dosage form is present in a substantially non-releasable form (i.e., "sequestered") when the dosage form is administered intact as directed. Preferably, because the aversive agent is present in the dosage form in a substantially non-releasable form, it is not substantially released in the gastrointestinal tract when the dosage form is orally administered intact.

In other embodiments, the aversive agent may not be "sequestered" as disclosed above wherein the aversive agent is not released or minimally released from an intact dosage form, but may have a modified or sustained release so as not to dump the aversive agent in a particular section of the gastrointestinal tract, e.g. the stomach, where it may cause an unwanted effect such as excessive irritation. The aversive agent can be combined with an enteric carrier to delay its release or combined with a carrier to provide a sustained release of the aversive agent. However, it is contemplated in the present invention that the aversive agent will preferably not have any significant side effect (e.g., gastrointestinal side

4

effect) even if all of the aversive agent is immediately released upon oral administration of an intact dosage form as directed.

The aversive agent(s) can also be in the dosage form in releasable form and non-releasable form in any combination. For example, a dosage form can have a bittering agent, irritant, gel or combination thereof in releasable form and non-releasable form as disclosed in U.S. Application entitled "Pharmaceutical Formulations Containing Opioid Agonist, Releasable Antagonist, and Sequestered Antagonist" filed Aug. 6, 2002, the disclosure of which is hereby incorporated by reference in its entirety.

The term "aversive agent" is defined for purposes of the present invention to mean a bittering agent, an irritant, a gelling agent, or combinations thereof.

The term "tampered dosage form" is defined for purposes of the present invention to mean that the dosage form has been manipulated by mechanical, thermal, and/or chemical means which changes the physical properties of the dosage form, e.g., to liberate the opioid agonist for immediate release if it is in sustained release form, or to make the opioid agonist available for inappropriate use such as administration by an alternate route, e.g., parenterally. The tampering can be, e.g., by means of crushing, shearing, grinding, chewing, dissolution in a solvent, heating, (e.g., greater than about 45° C.), or any combination thereof.

The term "substantially non-releasable form" for purposes of the present invention refers to an aversive agent that is not released or substantially not released at one hour after the intact dosage form containing an opioid agonist and at least one aversive agent is orally administered (i.e., without having been tampered with). The aversive agent in a substantially non-releasable form may be prepared in accordance with the teachings of U.S. application Ser. No. 09/781,081, entitled "Tamper Resistant Oral Opioid Agonist Formulations" filed Feb. 8, 2001, the disclosure of which is hereby incorporated by reference in its entirety, which describes a dosage form comprising an opioid antagonist in a substantially non-releasable form. For purposes of the present invention, the amount released after oral administration of the intact dosage form may be measured in-vitro via the dissolution at 1 hour of the dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C. Such a dosage form is also referred to as comprising a "sequestered aversive agent" depending on the agent or agents which are not released or substantially not released. In certain preferred embodiments of the invention, the substantially non-releasable form of the aversive agent is resistant to laxatives (e.g., mineral oil) used to manage delayed colonic transit and resistant to achlorhydric states. Preferably, the aversive agent is not released or not substantially released 4, 8, 12 and/or 24 hours after oral administration.

The phrase "analgesic effectiveness" is defined for purposes of the present invention as a satisfactory reduction in or elimination of pain, along with a tolerable level of side effects, as determined by the human patient.

The term "sustained release" is defined for purposes of the present invention as the release of the opioid analgesic from the oral dosage form at such a rate that blood (e.g., plasma) concentrations (levels) are maintained within the therapeutic range but below toxic levels over an extended period of time, e.g., from about 12 to about 24 hours as compared to an immediate release product. Preferably the sustained release is sufficient to provide a twice-a-day or a once-a-day formulation.

The term "particles" of aversive agent, as used herein, refers to granules, spheroids, beads or pellets comprising the aversive agent. In certain preferred embodiments, the aver-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.